Everything below concerns TB-500. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Peppermint oil is under preliminary research for its potential as a short-term treatment for irritable bowel syndrome. High oral doses of peppermint oil (500 mg) can cause mucosal irritation and mimic heartburn. Peppermint oil capsules are licensed as a medicine in the UK for the treatment of irritable bowel syndrome (IBS). Preliminary research administering a tiny amount of the oil in order to lower the systolic aspect of blood pressure is in initial human trials in 2026. Peppermint oil and leaves have a cooling effect when used topically for muscle pain, nerve pain, relief from itching, or as a fragrance. Peppermint oil had supposed uses in ancient traditional medicine for minor gastrointestinal diseases.
Modern-day diabetes is associated with two terms in the Chinese language. The traditional term, xiāo kě (消渴), means "wasting-thirst" and correlates closely with diabetes in most instances of historical description. The more modern term, táng niǎo bìng (糖尿病), means "sugar urine disease", and is equivalent to diabetes mellitus. It has been suggested that the modern term is derived from exchanges with Ayurvedic practitioners who called the condition madhumeha ("honey urine"). Within the Sinosphere (regions of East and Southeast Asia historically influenced by the linguistic and literary traditions of the Chinese empire), this etymology has also been borrowed into Korean (tang nyo byeong [당뇨병]) and Japanese (tou nyou byou [とうにょうびょう]). Reviews of diabetology history in Traditional Chinese medicine have classified the diagnosis and treatment of xiāo kě (消渴) into four periods, summarized below. Classic texts provided a typology of the condition and outlined various recommendations on diagnosis, development, treatment, and prevention. Knowledge of wasting-thirst was integrated with knowledge of diabetes during the Qing dynasty.
== Biological role == DAO is involved in the physiology of digestion and other physiological processes, such as inflammation, immune response, and wound healing. Dysfunction of DAO has been associated with various diseases, including allergies, autoimmune disorders, and cancer. DAO also plays a role in healthy pregnancy in placental mammals. In case of a shortage or low enzymatic activity of diamine oxidase in the human body, it may appear as an allergy or histamine intolerance.
Sources: en.wikipedia.org
While the first transfusions had to be made directly from donor to receiver before coagulation, it was discovered that by adding anticoagulant and refrigerating the blood it was possible to store it for some days, thus opening the way for the development of blood banks. John Braxton Hicks was the first to experiment with chemical methods to prevent the coagulation of blood at St Mary's Hospital, London in the late-19th century. His attempts, using phosphate of soda, however, proved unsuccessful. The Belgian doctor Albert Hustin performed the first non-direct transfusion on March 27, 1914, though this involved a diluted solution of blood. The Argentine doctor Luis Agote used a much less diluted solution in November of the same year. Both used sodium citrate as an anticoagulant. The First World War (1914–1918) acted as a catalyst for the rapid development of blood banks and transfusion techniques. Francis Peyton Rous and Joseph R. Turner at the Rockefeller University (then The Rockefeller Institute for Medical Research) made the first important discoveries that blood typing was necessary to avoid blood clumping (coagulation) and blood samples could be preserved using chemical treatment. Their first report in March 1915 showed that gelatine, agar, blood serum extracts, starch and beef albumin proved to be useless preservatives.
=== Controversy === In addition to Trikafta's high list price, Vertex has actively worked to prevent LMICs from accessing this drug combination. This has led to groups of patients in three countries, namely India, Ukraine and South Africa, to initiate legal and regulatory actions to compel their governments to allow for the importation or local production of low-cost generic versions of Trikafta through compulsory licensing. In 2022, the estimated cost of manufacturing a year's supply of Trikafta was US$5,700.
== Awards and honours == 2000: Balzan Prize for Classical Antiquity 2002: Kenyon Medal for Classical Studies from the British Academy 2007: A book of essays on ancient Greek literature written for West on his 70th birthday West was a DPhil and DLitt of Oxford University, and was elected a Fellow of the British Academy, a Corresponding Member of the Akademie der Wissenschaften, Göttingen, and a Member of the Academia Europaea, London. Queen Elizabeth II appointed him a Member of the Order of Merit (OM) in the 2014 New Year Honours.
Sources: en.wikipedia.org
== Prolactin == Agonists: Growth hormone Human placental lactogen Placental growth hormone (growth hormone variant) Prolactin S179D-hPRL Somatotropin Antagonists: Δ1–9-G129R-hPRL Δ1–14-G129R-hPRL G120K-hGH G129R-hPRL Prolactin modulators: Prolactin inhibitors: D2 receptor agonists (e.g., bromocriptine, cabergoline); Prolactin releasers: D2 receptor antagonists (e.g., domperidone, metoclopramide, risperidone) Estrogens (e.g., estradiol) Progestogens (e.g., progesterone)
==== Finasteride for androgenetic alopecia (hair loss in men) ==== The most common adverse effects of finasteride taken for hair loss are a decrease in sex drive, erectile dysfunction, and a decrease in the amount of semen. In addition, finasteride has been reported in case reports to cause sexual problems that persist after stopping the medication. A 2012 update to the FDA label noted reports of decreased sex drive, problems with ejaculation and difficulty achieving an erection which continued after stopping the medication. The update also referenced reports of testicular pain and "male infertility and/or poor quality of semen." In 2025, the European Medicines Agency confirmed that suicidal thoughts can occur as a side effect of the hair-loss treatment finasteride and similar dutasteride. The majority of these reports involved patients taking the 1 mg dosage, typically prescribed for androgenetic alopecia, a hormone-related form of hair loss. However, the agency noted that the precise frequency of this adverse effect could not be determined from the data available. In October 2024, the EMA had initiated a review of both finasteride and dutasteride due to concerns over potential links to suicidal ideation. While finasteride—marketed by Organon as Propecia—already includes warnings about possible psychiatric effects, the EMA stated that the evidence did not support a similar link for dutasteride, sold by GSK under the brand name Avodart.
== Career == Bentley dropped out of high school to pursue his own acting career, and had practiced autographs by the age of 12. He had to take odd jobs in movie theaters, a fish market, and a grocery store, among other places as he waited for his big break. His appearance enabled him to play the part of teens even into his twenties, and he landed a variety of small parts in television series and movies before landing bigger roles. Debuting in a 1986 Starburst commercial, he began his career as a child actor appearing in television commercials and guest spots on various television series before landing a role on the short-lived but critically acclaimed television series South Central in 1994. His first feature film role came in the 1995 horror movie Tales from the Hood, about the inner-city ganglands, an anthology of four stories focused on the consequences of the gang lifestyle. In that particular film, he played Crazy K, a cold and angry character. He once played a teenage father who opted to stay home with his child instead of turn out for the high school football team in a public service television announcement. In 1995, South Central creator Ralph Farquhar cast Bentley in the series Moesha as Hakeem Campbell, the always hungry friend of Moesha, which ran for six seasons on UPN. After Moesha ended, Bentley continued acting while pursuing a career as a rapper in the highly anticipated recording group UPRIZE with Marché Meeks aka "Cartier" and Tyson Pearson "Typhoon". In 2001, he appeared as C-Money in The Wash opposite Dr. Dre and Snoop Dogg.
Attempts to contact by mail in the late 1890s failed. United Brothers of Friendship - Founded August 1, 1861, by young local students in day or night schools. In 1868, on the advice of their teacher, W.H. Gibson, the society reorganized. Many chapters were formed in Kentucky, and a statewide Grand Lodge was formed in 1871. After establishing chapters outside Kentucky a National Grand Lodge was formed. W.H. Gibson served as the first State Grand Master for five years and as National Grand Master for four years. Unofficial female auxiliaries were called the Sisters of Friendship until 1878 when the organization formed the official Sisters of the Mysterious Ten, organized in local Temples. In 1878 the Order had about 4,000 members. That was the year they decided to establish another auxiliary, the Knights of Friendship, based on the story of David and Jonathan. In 1892 the UBF had 100,000 members in 19 states and 2 territories with 30,000 in Missouri alone. It was known to be active in Kentucky, Missouri, Arkansas, Louisiana, Texas, Mississippi, Alabama, Tennessee, West Virginia, Virginia, the District of Columbia, Pennsylvania, New York, New Jersey, Michigan, Kansas, Colorado, Washington, Canada, the West Indies and Africa. While predominantly black, the order had white members. There was evidence that the Grand United Order of Odd Fellows had something to do with its founding. United Knights and Daughters of America - Headquartered in St. Louis, Missouri. Reportedly had many members in the Midwest. Attempts to contact the order in 1923 were unsuccessful.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.